NO20090968L - Fremgangsmater for a behandle multippel myeloma ved anvendelse av kombinasjonsterapier basert pa anti-CS1 antistoffer - Google Patents

Fremgangsmater for a behandle multippel myeloma ved anvendelse av kombinasjonsterapier basert pa anti-CS1 antistoffer

Info

Publication number
NO20090968L
NO20090968L NO20090968A NO20090968A NO20090968L NO 20090968 L NO20090968 L NO 20090968L NO 20090968 A NO20090968 A NO 20090968A NO 20090968 A NO20090968 A NO 20090968A NO 20090968 L NO20090968 L NO 20090968L
Authority
NO
Norway
Prior art keywords
multiple myeloma
antibodies
methods
combination therapy
therapy based
Prior art date
Application number
NO20090968A
Other languages
English (en)
Other versions
NO346835B1 (no
Inventor
Daniel Afar
Kenneth C Anderson
Yu-Tzu Tai
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090968(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of NO20090968L publication Critical patent/NO20090968L/no
Publication of NO346835B1 publication Critical patent/NO346835B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

Sammensetning egnet for behandling av multippel myelom hos et subjekt, som innbefatter en terapeutisk effektiv mengde av HuLuc63, en terapeutisk effektiv mengde av lenalidomid og/eller bortezomib, og en farmasøytisk akseptabel bærer, hvori nevnte sammensetning kan administreres i et enkelt eller multippelt doseringsregime.
NO20090968A 2006-08-07 2007-08-07 Anvendelse av anti-CS1 antistoffet HuLuc63 i kombinasjonsbehandlinger for behandling av multippelt myelom NO346835B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US94426207P 2007-06-15 2007-06-15
PCT/US2007/075403 WO2008019378A1 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (2)

Publication Number Publication Date
NO20090968L true NO20090968L (no) 2009-04-30
NO346835B1 NO346835B1 (no) 2023-01-23

Family

ID=38831279

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090968A NO346835B1 (no) 2006-08-07 2007-08-07 Anvendelse av anti-CS1 antistoffet HuLuc63 i kombinasjonsbehandlinger for behandling av multippelt myelom

Country Status (23)

Country Link
US (4) US8632772B2 (no)
EP (5) EP2068874B1 (no)
JP (1) JP5340935B2 (no)
CN (1) CN101686971B (no)
AU (1) AU2007281684C1 (no)
BR (1) BRPI0716647A2 (no)
CA (1) CA2660356C (no)
CY (5) CY1116247T1 (no)
DK (2) DK2068874T3 (no)
ES (2) ES2535437T3 (no)
HR (2) HRP20150449T1 (no)
HU (4) HUE029027T2 (no)
IL (2) IL196919A (no)
LT (4) LT2641601T (no)
LU (3) LU93275I2 (no)
MX (1) MX2009001441A (no)
NL (1) NL300840I2 (no)
NO (1) NO346835B1 (no)
NZ (1) NZ574978A (no)
PL (2) PL2641601T3 (no)
PT (2) PT2068874E (no)
SI (2) SI2068874T1 (no)
WO (1) WO2008019378A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007281684C1 (en) 2006-08-07 2013-12-19 Abbvie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
NZ574979A (en) * 2006-08-07 2012-06-29 Abbott Biotherapeutics Corp Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
WO2009149021A2 (en) 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
CA2727278A1 (en) 2008-06-16 2010-01-21 Immunogen, Inc. Novel synergistic effects
EP3090737A1 (en) * 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
CA2773579C (en) 2009-09-10 2019-01-15 Kyowa Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
US8841325B2 (en) * 2009-11-24 2014-09-23 Celgene Corporation Immunomodulatory compounds for the restoration of vitamin D sensitivity in vitamin D resistant tumor cells
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
WO2015069703A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
ES2707057T3 (es) * 2013-11-06 2019-04-02 Bristol Myers Squibb Co Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
LT3071597T (lt) * 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
AU2015305449B2 (en) * 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US10752902B2 (en) * 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
US10365280B2 (en) 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
AU2015339012B2 (en) 2014-10-31 2020-11-05 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
EP3227335A1 (en) 2014-12-04 2017-10-11 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
HUE054271T2 (hu) * 2015-05-13 2021-08-30 Morphosys Ag Mielóma Multiplex (MM) kezelése
RS62352B1 (sr) 2015-06-29 2021-10-29 Bristol Myers Squibb Co Imunoterapijski režimi doziranja koji obuhvataju pomalidomid i anti-cs1 antitelo za lečenje kancera
CN109432398A (zh) * 2016-03-13 2019-03-08 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
US11124579B2 (en) 2017-03-29 2021-09-21 Agency For Science, Technology And Research Anti oligosaccharide antibody
JP2021504475A (ja) * 2017-11-22 2021-02-15 ヒルストリーム・バイオファーマ・インコーポレイテッド ボルテゾミブを含むポリマーナノ粒子
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US20220390455A1 (en) 2019-11-05 2022-12-08 Bristol-Myers Squibb Company M-protein assays and uses thereof
CN115368462B (zh) * 2022-07-19 2026-01-02 合肥天港免疫药物有限公司 双特异性抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
US6143292A (en) 1995-05-25 2000-11-07 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2752124A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
AU2005302083A1 (en) * 2004-11-04 2006-05-11 Fibron Limited Treatment of B-cell malignancies
NZ574979A (en) 2006-08-07 2012-06-29 Abbott Biotherapeutics Corp Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
EP2069478A2 (en) 2006-08-07 2009-06-17 PDL BioPharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
AU2007281684C1 (en) 2006-08-07 2013-12-19 Abbvie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies

Also Published As

Publication number Publication date
PL2068874T3 (pl) 2015-06-30
AU2007281684B2 (en) 2013-05-16
IL243933A0 (en) 2016-04-21
PT2641601T (pt) 2016-10-14
AU2007281684A1 (en) 2008-02-14
DK2641601T3 (en) 2016-08-22
HK1129853A1 (en) 2009-12-11
US20170342150A1 (en) 2017-11-30
LU93277I2 (fr) 2016-12-27
US8632772B2 (en) 2014-01-21
LTPA2016029I1 (lt) 2016-11-10
WO2008019378A1 (en) 2008-02-14
HRP20161284T1 (hr) 2016-12-16
EP2068874B1 (en) 2015-01-28
CY1117992T1 (el) 2017-05-17
US20140322201A1 (en) 2014-10-30
PL2641601T3 (pl) 2017-01-31
AU2007281684C1 (en) 2013-12-19
LTC2068874I2 (lt) 2018-11-12
CA2660356C (en) 2016-04-05
EP2068874A1 (en) 2009-06-17
CN101686971A (zh) 2010-03-31
EP2641601A1 (en) 2013-09-25
MX2009001441A (es) 2009-07-06
ES2589302T3 (es) 2016-11-11
CY1116247T1 (el) 2017-02-08
SI2068874T1 (sl) 2015-06-30
LT2641601T (lt) 2016-10-10
LU93275I2 (fr) 2016-12-27
CA2660356A1 (en) 2008-02-14
CY2016036I1 (el) 2017-07-12
EP2641600A1 (en) 2013-09-25
CY2016038I1 (el) 2017-07-12
SI2641601T1 (sl) 2016-11-30
HUS1600043I1 (hu) 2016-12-28
US20080152646A1 (en) 2008-06-26
LTPA2016030I1 (lt) 2016-11-10
HRP20150449T1 (xx) 2015-06-05
US20160137735A1 (en) 2016-05-19
PT2068874E (pt) 2015-05-21
HUE029027T2 (en) 2017-01-30
CY2016036I2 (el) 2017-07-12
IL196919A (en) 2016-03-31
LTPA2016031I1 (lt) 2016-11-10
EP3115049A1 (en) 2017-01-11
CY2016037I1 (el) 2017-07-12
HUS1600044I1 (hu) 2016-12-28
DK2068874T3 (da) 2015-04-27
LU93276I2 (fr) 2016-12-27
IL196919A0 (en) 2009-11-18
CN101686971B (zh) 2013-09-11
EP2641601B8 (en) 2016-09-21
NZ574978A (en) 2012-08-31
BRPI0716647A2 (pt) 2017-05-16
NL300840I2 (no) 2017-01-03
ES2535437T3 (es) 2015-05-11
EP2641601B1 (en) 2016-07-06
EP2942057A1 (en) 2015-11-11
HUS1600045I1 (hu) 2016-12-28
JP2010500371A (ja) 2010-01-07
NO346835B1 (no) 2023-01-23
JP5340935B2 (ja) 2013-11-13

Similar Documents

Publication Publication Date Title
NO20090968L (no) Fremgangsmater for a behandle multippel myeloma ved anvendelse av kombinasjonsterapier basert pa anti-CS1 antistoffer
MX2007005179A (es) Formas de dosificacion.
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX2016008362A (es) Combinaciones farmaceuticas.
SG157365A1 (en) Compositions and methods for treating neoplastic diseases
MX2009012598A (es) Formas de dosis que comprenden vx-950 y su regimen de dosificacion.
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
WO2007131168A3 (en) Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
EP3974453A3 (en) Agents and methods for treating diseases that correlate with bcma expression
WO2007103510A3 (en) Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
NO20090969L (no) Sammensetninger og fremgangsmater som anvender anti-CS1 antistoffer for a behandle multippel myeloma
EA200802324A1 (ru) Новая форма введения рацекадотрила
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
WO2009138186A3 (de) SEQUENTIELLE VERARBEITUNG VON 20,20,21,21-PENTAFLUOR-17-HYDROXY-11β-[4-(HYDROXYACETYL) PHENYL] -19-NOR-17α-PREGNA-4,9-DIEN-3-ON UND EINEM ODER MEHREREN GESTAGENEN ZUR BEHANDLUNG GYNÄKOLOGISCHER ERKRANKUNGEN
WO2013104050A3 (en) Methods of treating triple negative breast cancer and basal-like breast cancer using inhibitors against kidney associated 1 (kaag1) inhibitor
UA115250C2 (uk) Фармацевтичні комбінації
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
WO2007149543A3 (en) Scar treatment using protein phosphatase inhibitors
DK1603584T3 (da) Aplidine til behandling af multipelt myelom
NO20070763L (no) Kombinasjonsterapi med radiomerket anti-CD20-antistoff i behandlingen av B-cellelymfom

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: DANA FARBER CANCER INSTITUTE INC, US